Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
NextCure Inc
NXTC | US
11.64
USD0.43
3.84%
NXTC | US
About NextCure Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
10/04/2026
Close
11.64
Open
11.30
High
11.68
Low
10.69
NextCure Inc. a clinical-stage biopharmaceutical company engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410 an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762 a monoclonal antibody that binds specifically to B7-H4 a protein expressed on multiple tumor types; and NC525 a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure Inc. was incorporated in 2015 and is headquartered in Beltsville Maryland.
View LessNXTC | US
Risk
75.4
Sharpe
1.82
Luna's Score
61/100
Recommendation
Hold
Luna says (NXTC | US)
What's Working
Strength based on increasing price with high volume
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Sharpe Ratio (> 1.2)
What's not Working
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
Declining Revenue (< 0%)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
45.4%1 month
75.4%3 months
63.9%6 months
118.8%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
0.45
Debt to equity
0.07
Debt to assets
0.06
Ent. to EBITDA
0.51
Ent. to rev.
1.62
PEG
-
Other Fundamentals
EBITDA
-60.40M
MarketCap
325.64M
MarketCap(USD)
325.64M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-100.00
Ret. on equity
-54.75
Short ratio
1.87
Short perc.
0.29
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
3.37
Range1M
5.54
Range3M
5.83
Volumes: Market Activity
Rel. volume
1.71
Price X volume
797.51K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.51 | - | Par |
| Ent. to Revenue | 1.62 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.45 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 63.90 | - | Par |
| Debt to Equity | 0.07 | -1.23 | Expensive |
| Debt to Assets | 0.06 | 0.25 | Cheaper |
| Market Cap | 325.64M | - | Emerging |
